Scope and Claims Analysis for U.S. Patent 12,214,083: Amorphous Solid-Dispersion Mini-Tablets for CFTR-Mediated Pediatric Disease
Executive summary
U.S. Patent 12,214,083 claims a tightly defined unit-dose, mini-tablet granule/mini-tablet composition built around an amorphous active (Compound 1: N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide) formulated as a specific amorphous solid dispersion with HPMCAS and SLS, then blended with mannitol/lactose, sucralose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate. The claim set also ties the formulation to pediatric CFTR-mediated disease treatment, with multiple dependent claims narrowing patient age bands and weight, and narrowing to gating mutations (e.g., G551D, G178R and others).
The enforceable claim “core” is not merely “amorphous drug in a tablet.” It is the intersection of: (i) amorphous content thresholds (crystalline limits), (ii) solid dispersion composition and wt% ranges, (iii) unit dose amount and unit-dose form as mini-tablets, (iv) specific excipient system and ratios, and (v) CFTR-mediated pediatric treatment constraints for method claims.
How broad is U.S. Patent 12,214,083 claim 1 on amorphous Compound 1 solid dispersion?
Short answer: Claim 1 is broad on the end product goal (unit-dose formulation of amorphous Compound 1) but narrow on how that goal is met (exact solid dispersion composition bands, exact excipient system, and crystalline/amorphous thresholds).
What is claimed in composition claim 1 (structural elements)
Claim 1 requires a pharmaceutical composition in a unit dose form comprising a plurality of granules or mini-tablets with a defined multi-part formulation:
A. Solid dispersion component (critical limitation)
Solid dispersion is present at 30 to 40 wt% of the composition and must have:
- ~80 wt% amorphous Compound 1 (by weight of the dispersion)
- ~19.5 wt% HPMCAS
- ~0.5 wt% SLS
This is a high-precision “recipe within the recipe.” Even if the overall tablet composition is close, failing the dispersion composition (especially the HPMCAS and SLS ratios) is an infringement miss for claim 1.
B. Mannitol/lactose matrix component
Claim 1 requires mannitol and lactose totaling 30 to 60 wt% of the composition, with a fixed ratio:
This ratio is another tight hinge. A different sugar/polyol system or different ratio would likely fall outside the literal claim.
C. Sweetener
D. Disintegrant
- Croscarmellose sodium: 1.5 to 8 wt%
E. Glidant / anti-adherent
- Colloidal silicon dioxide: 0.1 to 5 wt%
F. Lubricant
- Magnesium stearate: 0.1 to 7 wt%
G. Amorphous/crystalline thresholds (critical limitation)
- Unit dose form comprises at least ~5 mg of amorphous Compound 1
- Less than ~15 wt% of the Compound 1 is crystalline
The crystalline threshold is the definitional boundary between “amorphous” as claimed and “partly crystalline.” It drives both enforceability and potential design-around: formulation work that shifts the crystalline content upward or changes the way crystalline fraction is measured may attempt avoidance (subject to interpretation and testing standards in the specification).
What does “granules or mini-tablets” do for claim scope?
Claim 1 is written to cover both:
- a plurality of granules, or
- a plurality of mini-tablets.
That drafting choice broadens physical form coverage but still ties the unit-dose composition to the same excipient system and the same dispersion and crystalline limits.
Claim 1 does not require tablet hardness, coating, or dissolution rate
No explicit hardness, disintegration time, dissolution profiles, or manufacturing steps are recited in the claim text provided. That matters for scope: infringement arguments can focus on composition/testing rather than performance parameter correspondence.
What are the strongest narrowing features in dependent claims 2–12 (form and dose geometry)?
Short answer: The most constraining dependent claims tighten (i) crystalline content further to “very low” levels, (ii) solid dispersion wt% and unit-dose mini-tablet count, and (iii) discrete unit doses (50 mg, 75 mg amorphous Compound 1).
Crystalline content narrowing
- Claim 2: less than 5 wt% crystalline Compound 1
- Claim 3: 0 wt% crystalline Compound 1
These dependent claims compress the admissible amorphous state. If a competitor formulation yields nonzero crystalline fraction, it may still infringe claim 1 (less than 15% crystalline) but could avoid claims 2–3.
Excipient placement constraint
- Claim 4: composition does not comprise SLS outside of the solid dispersion
This is a meaningful design-around lever. If an accused product uses SLS as an additional excipient elsewhere (binder, wetting, blend aid, etc.), it could be excluded from claim 4 while still potentially meeting claim 1 unless claim 1 is interpreted to implicitly permit additional SLS (claim 1 only states SLS content as part of the solid dispersion composition; claim 4 expressly limits outside dispersion).
Discrete dose amounts and solid dispersion loading
- Claim 5: unit dose comprises about 50 mg amorphous Compound 1
- Claim 6: about 75 mg amorphous Compound 1
- Claim 9: solid dispersion about 35 wt% and unit dose comprises about 26 mini-tablets
- Claim 11: solid dispersion about 35 wt% and unit dose comprises about 39 mini-tablets
- Claims 10 and 12 attach 50 mg / 75 mg with the above mini-tablet counts.
These dependents create a matrix of protected commercial “SKUs” by dose size and mini-tablet count.
Mini-tablet physical geometry
- Claim 7: 25 to 40 mini-tablets
- Claim 8: mini-tablet shape: cylinder-like, oval-like, cone-like, sphere-like, ellipsis-like, polygon-like, or combinations; longest dimension/diameter about 2 mm
This geometry language narrows form factor for claims 7–8. A competitor using different unit geometry (different count range or significantly different size) can avoid those dependent claims while still potentially meeting claim 1 if granules are used or if mini-tablet count/size remains within claim bounds.
How broad are the method-of-use claims 13–20 for CFTR-mediated pediatric disease?
Short answer: The method claims are relatively narrow because they tie treatment to pediatric age/weight windows and, for some dependents, to specific CFTR gating mutations.
Claim 13: pediatric method wrapper
- Treat or lessen severity of CFTR mediated disease in a pediatric patient by administering a composition of claim 1.
This claim inherits the strict formulation limitations of claim 1. If a product does not meet claim 1 composition boundaries, method claims may fail.
Claim 14: cystic fibrosis
CFTR mediated disease = cystic fibrosis.
Claim 15–16: gating mutation set
- Patient possesses a CFTR gating mutation
- mutation is selected from:
- G551D, G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N
This is an enumerated list, so literal infringement for dependents depends on whether the patient’s mutation is on the list.
Age constraints
- Claim 17: patient age 2 through 5 years
- Claim 18: patient age 0 through 2 years
Weight constraints
- Claim 19: patient weighs 14 or more kilograms
- Claim 20: patient weighs less than 14 kilograms
These dependents can combine with the mutation and age dependents, producing a set of protected patient-treatment populations aligned to dosing feasibility.
What “infringement map” emerges from the claim structure (where competitors can break out)?
Short answer: The claim set provides multiple technical “escape points”: dispersion composition, crystalline fraction, SLS placement, and mini-tablet form factor.
Primary infringement anchors (hard to change without re-engineering)
- Solid dispersion composition: Compound 1/HPMCAS/SLS wt% within the dispersion (80/19.5/0.5) and dispersion wt% in the final unit composition (30–40 wt%).
- Crystalline limits: <15 wt% crystalline; and in dependents <5 wt% or 0 wt%.
- Mannitol/lactose ratio: 1:3 and total 30–60 wt%.
- Excipients presence and ranges: sucralose, croscarmellose, colloidal silicon dioxide, magnesium stearate.
Secondary “avoidance” levers
- SLS outside dispersion (claim 4)
- Mini-tablet count range (claim 7) and ~2 mm longest dimension (claim 8)
- Exact unit dose amounts (claims 5–6, 10, 12)
Competitor strategies typically cluster around: using a different polymer (instead of HPMCAS), shifting amorphous management to change crystalline fraction, altering sugar/polyol system or ratio, or changing SLS use pattern. If a competitor changes any of these, they can potentially avoid claim 1 and therefore also avoid the method claims 13–20.
How many distinct protected claim “territories” exist across claims 1–20?
Short answer: At least four: (i) the base amorphous solid-disperison mini-tablet composition (claim 1), (ii) more stringent amorphous purity (claims 2–3), (iii) excipient placement (claim 4), and (iv) product geometry/dosing embodiments plus patient-treatment subsets (claims 5–12 and 13–20).
Claim territory breakdown
| Claim(s) |
Territory |
What changes to avoid |
| 1 |
Base composition |
Change dispersion recipe (HPMCAS/SLS), dispersion wt%, mannitol:lactose ratio, crystalline threshold, excipient ranges |
| 2–3 |
Amorphous purity |
Allow ≥5 wt% or ≥1 wt% crystalline (depending on evidence/threshold), or fail “0 crystalline” |
| 4 |
SLS placement |
Use SLS outside dispersion |
| 5–6 |
Dose size |
Use different amorphous mg per unit dose (but may still infringe claim 1) |
| 7–8 |
Mini-tablet count/size/shape |
Use outside 25–40 count range or outside ~2 mm dimension |
| 9–12 |
Dispersion wt% + mini-tablet count + dose |
Use different dispersion wt% or different mini-tablet count for the same dose range |
| 13–14 |
Pediatric CFTR disease (CF) wrapper |
Avoid claim 1 composition; otherwise age likely still can infringe claim 13 |
| 15–16 |
Gating mutation list |
Use for patients with non-listed mutation, or different indication claim framing |
| 17–18 |
Age bands |
Treat outside those windows (affects dependent claims) |
| 19–20 |
Weight bands |
Treat outside those windows (affects dependent claims) |
What does this patent landscape imply for generics or next-in-class pediatric formulations (U.S.)?
Short answer: The claim set is composition-centric, so generic risk hinges on matching the solid dispersion and excipient architecture while achieving the crystalline fraction thresholds. For method claims, risk depends on whether an applicant’s pediatric labeling and prescribed patient populations align to the claim 13–20 dependents.
Orange Book status and Paragraph IV strategy
No Orange Book bibliographic data was provided in the prompt, so the landscape cannot be mapped to specific Orange Book listings, FDA application numbers, or patent codes. The actionable point remains: Paragraph IV challenges targeting formulation patents like this typically require showing non-infringement (different formulation architecture or different crystalline content) and/or invalidity.
Design-around scenarios that directly map to limitations
- Swap out HPMCAS for another polymer and re-optimize dispersion: likely misses the dispersion composition limitation.
- Change SLS level in the dispersion: likely misses the 0.5 wt% dispersion SLS requirement.
- Maintain dispersion but broaden crystalline fraction above 15 wt%: may avoid claim 1 and all dependents about crystalline content.
- Use different sweetener or disintegrant system: avoids dependent excipient range limits.
- Use granules instead of mini-tablets: claim 1 still covers granules, so that change alone is insufficient unless the product also changes the required dispersion and excipient system.
- Alter mini-tablet count/size to outside 25–40 or outside ~2 mm: can avoid dependent claims 7–8 and 9–12, but not claim 1.
How do claims 1 and 13 interact: what is the practical enforceability for pediatric CFTR dosing?
Short answer: Claim 13 is not independently broad. It is tethered to administering a claim 1 composition. That means the decisive litigation fact pattern is whether the accused pediatric drug product meets the claim 1 formulation and crystalline constraints.
Enforceability chain
- Prove the product is administered to a pediatric patient for CFTR mediated disease.
- Prove the administered product satisfies claim 1 composition requirements.
- For dependents 14–20, add proof of cystic fibrosis, gating mutation status, age, and/or weight.
In practice, pharmaceutical litigation on formulation patents often turns on expert testing: dispersion composition fidelity, crystalline fraction quantification, and excipient presence/absence.
Claim coverage comparison: which parts are most “patentable” vs most “obviousness vulnerable”?
Short answer: The novelty-resilient aspects are the specific composition architecture (dispersion recipe with tight wt% values, mannitol:lactose 1:3, and multi-excipient blend) paired with crystalline fraction limits. Obviousness arguments typically target the polymer/surfactant selection and amorphous stabilization generally, but literal formulation constraints make the claim harder to beat if competitors’ formulations are substantially different.
Bloomberg-style claim-strength view (structural)
- Strength drivers
- Multiple independent constraints that must all be met simultaneously.
- Quantitative crystalline fraction limits.
- Quantitative dispersion recipe wt% and dispersion wt% in final blend.
- Possible weakness drivers (depending on the file history and prior art)
- Polymer and amorphous solid dispersion concepts can be prior art crowded.
- If prior art already discloses similar excipient systems and similar amorphous thresholds, obviousness may target overlapping ranges.
- If the active name “Compound 1” corresponds to a known drug, prior art can attack only the combination novelty rather than the active itself.
This assessment cannot be validated against cited references because the prompt provides only claim text, not specification, prosecution history, or cited art.
Key Takeaways
- U.S. 12,214,083 protects a specific pediatric-friendly unit dose mini-tablet/granule architecture built on an amorphous solid dispersion (Compound 1/HPMCAS/SLS at ~80/19.5/0.5) at 30–40 wt% of the composition.
- The enforceable boundary is not “amorphous drug in a tablet.” It is the combination of: (i) dispersion recipe, (ii) mannitol:lactose 1:3 in 30–60 wt%, (iii) sucralose/croscarmellose/colloidal silicon dioxide/magnesium stearate in defined ranges, and (iv) crystalline fraction <15 wt% (with dependent tiers <5 wt% and 0 wt%).
- Dependent claims add protection for particular dose sizes (about 50 mg/75 mg), mini-tablet count (25–40), and ~2 mm dimension, plus SLS restricted to the dispersion.
- Method claims for CFTR-mediated pediatric treatment (including cystic fibrosis and specific gating mutations) are tethered to infringement of the claim 1 formulation.
- For competitive or generic risk, the decisive question is whether an accused product matches the solid dispersion wt% recipe and achieves the claimed crystalline fraction while using the same excipient architecture.
FAQs
1) What crystalline threshold protects U.S. 12,214,083 claim 1?
Less than about 15 wt% of Compound 1 is crystalline in the unit dose form.
2) Does U.S. 12,214,083 require mini-tablets specifically?
Claim 1 allows a plurality of granules or mini-tablets; dependent claims narrow mini-tablets via count and size.
3) What is the mannitol to lactose ratio required by the composition claims?
About 1:3 mannitol to lactose.
4) Which CFTR gating mutations are enumerated in dependent claims?
G551D, G178R, G551S, G970R, G1244E, S1255P, G1349D, S549N, S549R, S1251N.
5) How do the method claims depend on the formulation claims?
Method claim 13 administers “the pharmaceutical composition of claim 1,” so method infringement requires the product meet claim 1 composition and crystalline limits.
References
- US Patent 12,214,083. (Claims excerpt provided in prompt).
